Related Experiment Videos
Neuropathological changes in the caudate nucleus elicited by MPTP and their prevention by monoamine oxidase
1Department of Anatomy, Robert Wood Johnson Medical School, University of Medicine and Dentistry, Piscataway, NJ 08854.
Abstract:
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin producing parkinsonism, causes an obvious reduction in tyrosine hydroxylase (TH) activity in the caudate nucleus. This depletion of TH activity is due to degeneration of TH-positive punctate dopaminergic terminals. The disappearance of these terminals unmasks the presence of long branching, varicose preterminal fibers, which may be sprouting after degeneration of their terminal arborizations. Glial cells, normally sparse with delicate processes, undergo intense increase in number and a robust hypertrophy. All of these changes are prevented completely by administration of deprenyl, a monoamine oxidase inhibitor, before and after MPTP. These neuropathological effects are additional manifestations of the dopaminergic neurotoxicity induced by MPTP. The metabolism of MPTP, which is blocked by monoamine oxidase inhibition, is apparently necessary for the expression of toxicity in the brain by this neurotoxin.
Insights
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes parkinsonism by damaging dopamine neurons. Deprenyl, a monoamine oxidase inhibitor, completely prevents these neurotoxic effects, highlighting MPTP metabolism
Area of Science:
- Neuroscience
- Toxicology
Background:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces parkinsonism.
- MPTP causes a significant reduction in tyrosine hydroxylase (TH) activity in the caudate nucleus.
Purpose of the Study:
- To investigate the neuropathological effects of MPTP on dopaminergic terminals and glial cells.
- To determine the protective role of deprenyl against MPTP-induced neurotoxicity.
Main Methods:
- Administration of MPTP to induce parkinsonism.
- Assessment of tyrosine hydroxylase (TH) activity and dopaminergic terminal degeneration.
- Observation of glial cell proliferation and hypertrophy.
- Evaluation of deprenyl's effects when administered before and after MPTP.
Main Results:
- MPTP caused degeneration of TH-positive dopaminergic terminals in the caudate nucleus.
- MPTP induced significant glial cell proliferation and hypertrophy.
- Deprenyl administration completely prevented MPTP-induced neuropathological changes.
- MPTP metabolism, inhibited by deprenyl, appears crucial for its neurotoxicity.
Conclusions:
- MPTP-induced parkinsonism involves dopaminergic neurotoxicity and glial activation.
- Deprenyl effectively protects against MPTP neurotoxicity, suggesting a role for monoamine oxidase in MPTP metabolism and toxicity.
- These findings provide insights into the mechanisms of dopaminergic neurodegeneration and potential therapeutic strategies.